2025 American Thyroid Association (ATA) Management Guidelines for Adults with Differentiated Thyroid Cancer

Domain

ATA 2015

ATA 2025

Key Change / Clinical Takeaway

Overall philosophy

Emphasis on de-escalation of therapy for low-risk disease; move away from “one-size-fits-all.”

Continues de-escalation, adds precision / molecular personalization and survivorship care.

2025 broadens from “less is more” to “tailor care precisely.”

Risk Stratification

ATA three-tier (low / intermediate / high) system; based mainly on histopathology, stage, and post-op findings.

Maintains 3-tier but integrates molecular markers, and refined dynamic risk stratification (based on response to therapy).

Risk models are now genomically informed; ongoing refinement for predicting recurrence.

Dynamic Response to Therapy

Introduced concept—adjust follow-up and TSH suppression based on response.

Reinforced with stronger data; uses both biochemical (Tg) and structural responses, plus genomic features.

Greater emphasis on real-time re-stratification of risk.

Molecular Testing (Diagnosis & Prognosis)

Discussed mainly for indeterminate nodules (Bethesda III/IV) to help decide surgery vs observation.

Expanded role: includes actionable mutation panels (BRAF, RET, NTRK, RAS, TERT, TP53) for both diagnosis and therapy selection.

From optional adjunct → core tool in risk and treatment decisions.

Germline & Familial Testing

Minimal mention (mainly medullary carcinoma context).

Encourages germline testing in certain familial non-medullary cases; introduces protocols for familial DTC screening.

Recognises genetic susceptibility in selected DTC cases.

Surgery (Extent & Indications)

Lobectomy acceptable for solitary, low-risk tumours ≤4 cm; total thyroidectomy for multifocal, high-risk, or >4 cm.

Retains this, but refines indications with molecular and imaging data; more explicit about when observation is safe.

Further validation of conservative surgery; avoids overtreatment.

Radioactive Iodine (RAI) Use

Recommended selectively based on risk; routine use discouraged for low-risk disease.

Same principles; now more selective, guided by postoperative Tg, molecular data, and dynamic response.

Continued RAI de-escalation, tighter criteria for benefit.

TSH Suppression Therapy

Stratified by risk: strong suppression for high-risk, moderate for intermediate, minimal for low-risk.

Similar framework, but stresses individualisation to minimise long-term harms (osteopenia, AF).

Emphasis on balancing benefit vs toxicity.

Radioiodine-Refractory (RAIR) DTC

Limited guidance; MKIs (sorafenib, lenvatinib) mentioned with caution.

Detailed algorithms: 1st-line MKIs (lenvatinib preferred), cabozantinib as 2nd-line; targeted therapy if actionable driver present (RET, NTRK, BRAF V600E, etc).

Major expansion: targeted therapy & sequencing guidance.

Targeted / Systemic Therapies

Only mentioned MKIs in passing; clinical trial participation advised.

Integrates RET inhibitors (selpercatinib, pralsetinib), NTRK inhibitors (larotrectinib, entrectinib), BRAF/MEK combinations, and MKIs.

Reflects precision oncology era—specific drug guidance included.

Surveillance Imaging & Follow-up

Annual ultrasound, Tg/anti-Tg levels, risk-based imaging intervals.

Dynamic: intensity adjusted to response category; introduces survivorship clinic model and mental health/QoL metrics.

From rigid schedule → personalised follow-up strategy.

Survivorship / Quality of Life

Little mention; focused on recurrence surveillance.

Dedicated section on QoL, fatigue, dysphonia, mental health, financial toxicity, fertility.

Formal inclusion of survivorship care as part of management.

Nodal Disease Management

Central neck dissection only if clinically indicated; limited prophylactic dissection.

Confirms same, with added data supporting targeted nodal resection only when proven disease.

Reinforces selective surgery.

Active Surveillance

Acceptable for microcarcinomas (<1 cm) in select low-risk patients.

Expanded endorsement with longer follow-up data; clearer criteria for initiation/cessation.

Active surveillance mainstreamed.

Pediatric / Young Adult Considerations

Separate guidelines (2015 pediatric ATA).

Cross-references new pediatric DTC 2022 ATA update; integration of transition-of-care principles.

Improves continuity into adult follow-up.

Evidence Quality & Grading

GRADE framework; evidence base limited for many items.

Continues GRADE; now supported by more RCTs, registry data, and real-world outcomes.

Higher evidence levels in systemic therapy and RAI domains.

Philosophical Shift

“Less is more” — reduce overtreatment.

“Precision and survivorship” — individualise to biology and patient experience.

Broader scope, integrating genomics + quality of life.